Optimal treatment for recurrent/metastatic head and neck cancer

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

(2010) Melarkode S. Ramakrishnan et al.   mAbs

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

(2009) J. Simon W. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck Cancer

(2009) Tawee Tanvetyanon et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

(2009) Nicholas J. Petrelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

(2009) Tanja Schneider-Merck et al.   JOURNAL OF IMMUNOLOGY

Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment

(2009) Shanthi Marur et al.   MAYO CLINIC PROCEEDINGS

Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone

(2008) B.-S. Kim et al.   ANNALS OF ONCOLOGY

Randomized Trial of Postoperative Reirradiation Combined With Chemotherapy After Salvage Surgery Compared With Salvage Surgery Alone in Head and Neck Carcinoma

(2008) François Janot et al.   JOURNAL OF CLINICAL ONCOLOGY

Recent Advances in Head and Neck Cancer

(2008) Robert I. Haddad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE